JPWO2020009216A1 - SseJタンパク質を用いたサルモネラワクチン - Google Patents
SseJタンパク質を用いたサルモネラワクチン Download PDFInfo
- Publication number
- JPWO2020009216A1 JPWO2020009216A1 JP2020529059A JP2020529059A JPWO2020009216A1 JP WO2020009216 A1 JPWO2020009216 A1 JP WO2020009216A1 JP 2020529059 A JP2020529059 A JP 2020529059A JP 2020529059 A JP2020529059 A JP 2020529059A JP WO2020009216 A1 JPWO2020009216 A1 JP WO2020009216A1
- Authority
- JP
- Japan
- Prior art keywords
- salmonella
- protein
- ssej
- vaccine
- salmonella spp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 56
- 229940124842 Salmonella vaccine Drugs 0.000 title description 4
- 241000607142 Salmonella Species 0.000 claims abstract description 64
- 229960005486 vaccine Drugs 0.000 claims abstract description 42
- 206010039438 Salmonella Infections Diseases 0.000 claims abstract description 9
- 206010039447 salmonellosis Diseases 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 22
- 230000001681 protective effect Effects 0.000 abstract description 11
- 235000018102 proteins Nutrition 0.000 description 53
- 241000894006 Bacteria Species 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 241001138501 Salmonella enterica Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108700008969 Salmonella SPI-2 Proteins 0.000 description 8
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 6
- 108010069584 Type III Secretion Systems Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 102000040739 Secretory proteins Human genes 0.000 description 4
- 108091058545 Secretory proteins Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 2
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Salmonella Typhimurium x3306株のDNAを鋳型として、プライマー(フォワード:CACCATGCCATTGAGTGTTGGACA/配列番号:3、リバース:TTATTCAGTGGAATAATGATGAGCT/配列番号:4)を用いてPCRを行った。
Salmonella Typhimurium x3306株、Salmonella Choleraesuis ATCC7001株、Salmonella Dublin 5230株の死菌(105CFU)および精製した組換えSseJタンパク質(10μg)をインコンプリートアジュバントと共に、BACB/cマウス(メス5週令)の皮下に免疫し、約2週間後に再度免疫した。免疫後2週間後に、Salmonella Typhimurium x3306株、Salmonella Choleraesuis ATCC7001株、Salmonella Dublin 5230株を、それぞれ106 CFU(LD50は104)、106 CFU(LD50は5x104)、106 CFU(LD50は5x104)経口感染させた。感染6時間前にマウスを絶食させ、その後10%重曹を50μl経口投与し、上記サルモネラ属菌をそれぞれ経口から感染させた。対照として、分泌タンパク質単独(10μg)、死菌単独(105CFU)、または無処置での検証も併せて行った。
・人工的に合成したプライマー配列
Claims (2)
- サルモネラ属菌由来のSseJタンパク質またはその免疫原性断片とサルモネラ属菌の死菌との組み合わせを含む、サルモネラ症から生体を防御するためのワクチン。
- 請求項1に記載のワクチンをサルモネラ属菌に感染する生体に投与する、サルモネラ症から生体を防御する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023076476A JP2023087090A (ja) | 2018-07-05 | 2023-05-08 | SseJタンパク質を用いたサルモネラワクチン |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018128150 | 2018-07-05 | ||
JP2018128150 | 2018-07-05 | ||
PCT/JP2019/026793 WO2020009216A1 (ja) | 2018-07-05 | 2019-07-05 | SseJタンパク質を用いたサルモネラワクチン |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023076476A Division JP2023087090A (ja) | 2018-07-05 | 2023-05-08 | SseJタンパク質を用いたサルモネラワクチン |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2020009216A1 true JPWO2020009216A1 (ja) | 2021-07-08 |
JP7281208B2 JP7281208B2 (ja) | 2023-05-25 |
Family
ID=69060443
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020529059A Active JP7281208B2 (ja) | 2018-07-05 | 2019-07-05 | SseJタンパク質を用いたサルモネラワクチン |
JP2023076476A Pending JP2023087090A (ja) | 2018-07-05 | 2023-05-08 | SseJタンパク質を用いたサルモネラワクチン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023076476A Pending JP2023087090A (ja) | 2018-07-05 | 2023-05-08 | SseJタンパク質を用いたサルモネラワクチン |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP7281208B2 (ja) |
WO (1) | WO2020009216A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016017620A1 (ja) * | 2014-07-28 | 2016-02-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | サルモネラワクチン |
-
2019
- 2019-07-05 WO PCT/JP2019/026793 patent/WO2020009216A1/ja active Application Filing
- 2019-07-05 JP JP2020529059A patent/JP7281208B2/ja active Active
-
2023
- 2023-05-08 JP JP2023076476A patent/JP2023087090A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016017620A1 (ja) * | 2014-07-28 | 2016-02-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | サルモネラワクチン |
Non-Patent Citations (1)
Title |
---|
GENG, SHIZHONG ET AL., VETERINARY MICROBIOLOGY, vol. 168, JPN6019028346, 2014, pages 388 - 394, ISSN: 0005008452 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020009216A1 (ja) | 2020-01-09 |
JP2023087090A (ja) | 2023-06-22 |
JP7281208B2 (ja) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9662380B2 (en) | C. perfringens alpha toxoid vaccine | |
Ghunaim et al. | Advances in vaccination against avian pathogenic Escherichia coli respiratory disease: potentials and limitations | |
Tizard | Vaccines for Veterinarians E-Book | |
Li et al. | Protective effects of chicken egg yolk antibody (IgY) against experimental Vibrio splendidus infection in the sea cucumber (Apostichopus japonicus) | |
US10603371B2 (en) | Attenuated Pasteurella multocida vaccines and methods of making and use thereof | |
US11285199B2 (en) | Vaccine composition comprising recombinant protein of Staphylococcus aureus attenuated enterotoxin and cytotoxin | |
ES2764173T3 (es) | Bacterias modificadas para vacunas mejoradas contra la brucelosis | |
JP6712760B2 (ja) | サルモネラワクチン | |
JP7281208B2 (ja) | SseJタンパク質を用いたサルモネラワクチン | |
US20140248273A1 (en) | Vaccine based on staphylococcal superantigen-like 3 protein (ssl3) | |
US20220241390A1 (en) | Vaccine composition comprising recombinant protein of staphylococcus aureus attenuated enterotoxin and cytotoxin | |
EP2991675B1 (en) | Campylobacter vaccine | |
KR20190061329A (ko) | 개선된 고스트 살모넬라 갈리나룸 사균체를 유효성분으로 포함하는 가금 티푸스의 예방 또는 치료용 백신 조성물 | |
Azeem et al. | Host immune responses and vaccination against avian pathogenic Escherichia coli-RETRACTED | |
Carver et al. | Vaccination with Siderophore receptors and porins protects against fowl cholera challenge by heterologous serotypes | |
RU2285539C2 (ru) | Молекулярная бивалентная вакцина для профилактики бруцеллеза и диарей, вызванных энтеропатогенными бактериями | |
KR20190120111A (ko) | 개선된 고스트 살모넬라 갈리나룸 사균체를 유효성분으로 포함하는 가금 티푸스의 예방 또는 치료용 백신 조성물 | |
Marwah et al. | THE EFFECT OF KILLED CORYNEBACTERIUM PSEUDOTUBERCULOSIS AND ITS TOXIN ON TETANUS HYPERIMMUNE SERUM PRODUCTION. | |
Windhorst | Controlling salmonella in poultry flocks by vaccination | |
PL218664B1 (pl) | Sposób ekspresji rekombinowanego białka błony zewnętrznej bakterii Gram-ujemnych i zastosowanie tego białka |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220315 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230328 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7281208 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |